An activated T-cell marker test uses flow cytometry to estimate how many T lymphocytes are showing signs of recent or ongoing stimulation. Laboratories may measure HLA-DR and CD38 separately or identify cells that express both markers, often within CD4 or CD8 T-cell groups. A higher percentage can occur when the immune system is responding to infection, severe inflammation, immune dysregulation, or another strong antigenic trigger. It does not identify the cause by itself.
This is a specialized test rather than a routine inflammation screen. Results depend on the laboratory’s antibody panel, gating method, cell population, and reporting format, so there is no single universal normal range. Clinicians interpret the pattern with symptoms, blood counts, ferritin, soluble IL-2 receptor, infection studies, and other immune tests. A markedly abnormal result may help document T-cell activation, but it cannot independently diagnose hemophagocytic lymphohistiocytosis, autoimmune disease, chronic infection, cancer, or immune exhaustion.
- The test measures activated T cells: It usually reports the percentage of CD4 or CD8 T cells expressing HLA-DR, CD38, or both.
- High results are nonspecific: Infection, hyperinflammation, recent vaccination, immune therapy, and several immune disorders can raise activated T-cell populations.
- There is no universal normal range: Reference limits and cutoffs vary by laboratory, age, cell subset, and flow-cytometry method.
- No fasting is usually required: A fresh blood sample is generally needed, and prompt transport matters because cell markers can change after collection.
- Interpretation requires context: The result is most useful when compared with symptoms, prior values, ferritin, soluble IL-2 receptor, cytokines, and infection testing.
Table of Contents
- What the Activated T-Cell Marker Test Measures
- How Flow Cytometry Produces the Result
- Why the Test Is Ordered
- Understanding High and Low Results
- Patterns Linked to Different Conditions
- Limits and Confounding Factors
- Preparation, Sample Handling, and Timing
- Follow-Up and When Care Is Urgent
What the Activated T-Cell Marker Test Measures
T cells are white blood cells that recognize infected, abnormal, or foreign cells and coordinate many parts of the immune response. Resting T cells can change their surface proteins after they encounter an antigen and receive activating signals. HLA-DR and CD38 are two proteins commonly used to identify this change.
HLA-DR is a major histocompatibility complex class II molecule. It is normally abundant on antigen-presenting cells such as B cells, monocytes, and dendritic cells. Resting T cells usually show little HLA-DR, but activated T cells can increase it. On a T cell, HLA-DR therefore acts as evidence of immune stimulation rather than as a marker of one specific disease.
CD38 is a multifunctional cell-surface enzyme and receptor. It appears on several immune-cell types and at different stages of cell development. Strong CD38 expression may be seen on recently activated T cells, but CD38 is not exclusively an activation marker. For example, some immature or newly produced T cells can express it, and plasma cells normally express CD38 strongly.
A laboratory often gains more information by looking for co-expression, meaning HLA-DR and CD38 are present on the same T cell. Reports may describe:
- HLA-DR-positive CD4 T cells
- HLA-DR-positive CD8 T cells
- CD38-positive or CD38-bright CD4 or CD8 T cells
- HLA-DR-positive, CD38-positive T cells
- HLA-DR-positive, CD38-high T cells
- Activated cells within naïve, central-memory, effector-memory, or terminal-effector T-cell compartments
The exact wording matters. “CD38 positive” can include a broader cell population than “CD38 high” or “CD38 bright.” Similarly, a percentage measured among all lymphocytes is not directly comparable with a percentage measured only among CD8 effector-memory cells.
This test measures cell phenotype, not the amount of an inflammatory protein dissolved in plasma. It differs from a cytokine panel, which measures soluble signaling molecules, and from a basic T-cell count, which focuses on how many T cells are present rather than how activated they appear.
How Flow Cytometry Produces the Result
The test is usually performed on anticoagulated whole blood. The laboratory mixes the sample with fluorescent antibodies that bind selected cell-surface proteins. A typical panel includes CD3 to identify T cells, CD4 and CD8 to separate major T-cell subsets, and antibodies against HLA-DR and CD38. More complex panels may add CD45RA, CCR7, CD27, CD45RO, or other markers to define maturation and memory compartments.
A flow cytometer passes cells one at a time through laser beams. The instrument records light scatter and the fluorescence emitted by each antibody label. Software then places cells into defined regions called gates. A simplified gating sequence may be:
- Select intact white blood cells and exclude debris.
- Remove cell doublets so two attached cells are not counted as one event.
- Identify lymphocytes by their light-scatter pattern.
- Select CD3-positive T cells.
- Divide them into CD4-positive and CD8-positive groups.
- Measure HLA-DR and CD38 expression within each selected group.
The final report may give a percentage, an absolute number of cells per microliter, median fluorescence intensity, or several of these measures. Percentage results show the proportion of a parent population that meets the laboratory’s definition of activated. Absolute counts combine that percentage with a cell count and may be influenced by lymphopenia or lymphocytosis. Fluorescence intensity reflects how strongly a marker is expressed, but it is especially dependent on instrument settings and laboratory standardization.
A report should ideally identify the parent population and the threshold used. For example, “12% of CD8 T cells are HLA-DR+CD38high” is more interpretable than “activated T cells 12%.” The clinician may also review the laboratory’s reference interval, specimen age, quality comments, and whether the assay is validated for clinical diagnosis or offered primarily as a laboratory-developed test.
When a broader picture is needed, the marker study may be part of a flow cytometry immune panel. That approach can show whether the activated population occurs alongside low CD4 cells, expanded CD8 cells, abnormal B-cell or NK-cell numbers, or an unusual lymphocyte distribution.
Why the Test Is Ordered
Clinicians order HLA-DR and CD38 testing when documenting T-cell activation could clarify an otherwise complex immune picture. It is most often used by immunologists, hematologists, infectious-disease specialists, rheumatologists, transplant teams, and specialized hospital laboratories.
One important use is the evaluation of hyperinflammatory syndromes. In hemophagocytic lymphohistiocytosis (HLH) and related immune-regulatory disorders, T cells and macrophages can become intensely activated. Studies have found that expanded HLA-DR-positive, CD38-high T-cell populations correlate with soluble IL-2 receptor and other markers of systemic immune activation. This can provide rapid cellular evidence of activation while the full diagnostic workup proceeds. It does not replace established clinical criteria, genetic testing, bone marrow evaluation, or the soluble IL-2 receptor test.
The test may also appear in selected evaluations of:
- Persistent or severe viral infection
- HIV-related immune activation, especially in research or specialized monitoring
- Tuberculosis biomarker studies
- Immune activation after transplantation
- Responses to vaccines, immune checkpoint inhibitors, cellular therapy, or other immunotherapies
- Primary immune-regulatory disorders
- Severe systemic inflammation when infection and immune dysregulation overlap
- Research studies of chronic inflammatory or autoimmune disease
In HIV care, CD38 and HLA-DR expression on CD8 T cells historically helped characterize immune activation and disease progression. Modern routine HIV monitoring relies mainly on viral load, CD4 count, treatment response, and clinical status. Activated T-cell markers may still be used in research or unusual specialist evaluations, but they are not a substitute for a CD4 count or HIV RNA test.
The test is sometimes ordered serially. A falling activated T-cell percentage after treatment may support improving immune activation, while persistent elevation may prompt a search for ongoing infection, uncontrolled inflammation, or another stimulus. Serial values are most meaningful when the same laboratory uses the same panel, gating strategy, and specimen conditions.
Understanding High and Low Results
A high result means that more T cells than expected meet the laboratory’s activation-marker definition. It does not show why those cells are activated, whether they are functioning effectively, or whether the activation is harmful.
There is no universal cutoff that applies to every HLA-DR/CD38 report. Published studies have used different combinations, including HLA-DR alone, CD38 alone, dual-positive cells, and CD38-high cells within selected memory subsets. Laboratories also differ in antibody clones, fluorochromes, instruments, compensation, gating, and reference populations. Children may have different T-cell distributions from adults, and acute illness may shift results rapidly.
Interpretation should start with four questions:
| Question | Why it changes the meaning |
|---|---|
| Which cells were measured? | CD4, CD8, total CD3, and effector-memory populations can show different activation patterns. |
| How was positivity defined? | CD38-positive, CD38-bright, and dual-positive gates are not interchangeable. |
| Was the result a percentage or absolute count? | A high percentage can coexist with a low absolute number when total lymphocytes are reduced. |
| What reference interval did the laboratory use? | Method-specific reference limits are more useful than a cutoff taken from another laboratory or study. |
A modest increase may reflect a recent immune event, such as a viral illness or vaccination. A large expansion—especially of CD38-high/HLA-DR-positive CD8 T cells—can occur with strong antigenic stimulation and hyperinflammation. The result becomes more concerning when it accompanies persistent fever, falling blood counts, very high ferritin, liver dysfunction, coagulopathy, organ injury, or neurologic change.
A normal or low result means the measured activated population is not increased by that assay at that time. It does not prove that no inflammation, infection, autoimmune process, or immune deficiency exists. Activation may occur in tissues rather than blood, may involve other immune cells, or may be missed because the sample was collected before or after the circulating peak. Immunosuppressive treatment can also reduce marker expression.
“Low activated T cells” is rarely interpreted as a stand-alone deficiency. If immune weakness is suspected, clinicians usually focus on total lymphocyte counts, CD4 and CD8 numbers, immunoglobulins, vaccine responses, lymphocyte proliferation, and the clinical history of infections. The lymphocyte subset panel is often more informative for cell quantity and distribution.
Patterns Linked to Different Conditions
The same marker pattern can appear in different diseases, but the surrounding laboratory and clinical picture may help narrow the possibilities.
Acute infection and recovery
Viral and some bacterial infections activate antigen-specific T cells. HLA-DR and CD38 can rise during the active immune response and decline as antigen burden falls. The timing is not identical for every pathogen or patient. In antigen-specific research assays, activation markers have helped distinguish active tuberculosis from latent infection and track change after treatment. Routine diagnosis still depends on microbiology, imaging, exposure history, and validated pathogen-specific tests.
Recent infection may produce a temporary expansion without indicating a chronic immune disorder. A repeat test after recovery can help show whether the change was transient. Symptoms, C-reactive protein, blood count, liver enzymes, and pathogen testing provide essential context.
HLH and related hyperinflammation
HLH can cause fever, cytopenias, enlarged spleen, liver abnormalities, coagulopathy, neurologic symptoms, and very high inflammatory markers. Activated CD8 T cells are often prominent in some forms, especially when a viral or immune-regulatory trigger drives the syndrome. A high HLA-DR+CD38high population can support the presence of substantial T-cell activation and may correlate with soluble IL-2 receptor, CXCL9, and ferritin.
The finding remains nonspecific. Sepsis, severe infection, malignancy, and other inflammatory states can overlap clinically and biologically with HLH. Clinicians use the full pattern rather than treating one flow-cytometry value as diagnostic.
Chronic HIV infection
Persistent immune activation has long been recognized in HIV. Activated CD8 T-cell populations may remain increased even when antiretroviral therapy suppresses plasma virus, although effective treatment generally improves immune activation. Today, viral load and CD4 count guide routine treatment decisions. HLA-DR/CD38 results are more likely to be used in studies of immune recovery, inflammation, and viral reservoirs than in ordinary clinic visits.
The CD4/CD8 ratio can add a different view of immune balance, but it also cannot determine the cause of activation by itself.
Immune therapy, transplantation, and cancer
Therapies that deliberately stimulate or redirect T cells can change activation markers. This may occur after checkpoint inhibitors, bispecific antibodies, CAR T-cell therapy, therapeutic vaccination, or transplantation. In these settings, the expected pattern depends on treatment timing and the clinical question. Activated cells may represent desired antitumor activity, treatment-related inflammation, infection, rejection, or a mixture of processes.
CD38 and HLA-DR can also be expressed by malignant or non-T-cell populations. Correct gating is therefore essential. A report should not be interpreted simply by seeing the words “CD38 positive” or “HLA-DR positive”; the cell lineage and marker combination determine the meaning.
Limits and Confounding Factors
The test’s main limitation is lack of disease specificity. It demonstrates a phenotype associated with activation, but many triggers can create that phenotype. It also cannot tell whether the cells are protective, dysfunctional, exhausted, or directly causing tissue injury.
Several factors can alter the result:
- Recent infection or vaccination: Both can temporarily increase activated T cells.
- Corticosteroids and other immunosuppressants: Treatment may reduce circulating cells or marker expression.
- Biologic and cellular therapies: These can change both cell number and phenotype in treatment-specific ways.
- Age: Children, adults, and older adults do not have identical immune-cell distributions.
- Time from symptom onset: Activated populations may rise and fall over days or weeks.
- Specimen delay: Aging blood can lose cell viability or show altered marker intensity.
- Lymphopenia: A high percentage may represent a small absolute number of cells.
- Laboratory method: Different panels and gates can classify the same borderline population differently.
CD38 also has biological meanings beyond activation. It may be expressed on developing lymphocytes and certain plasma-cell populations. HLA-DR is abundant on antigen-presenting cells and can be altered in other immune states. Accurate analysis must first establish that the events are T cells and then identify the relevant subset.
Another limitation is that peripheral blood is only one compartment. Activated cells may migrate into lymph nodes, lungs, liver, skin, joints, or other tissues. A normal blood result cannot exclude tissue-focused inflammation. Conversely, a blood expansion does not identify which organ, if any, is being injured.
Comparing values from different laboratories is risky. Even when both reports use the same marker names, they may use different antibody clones, instruments, controls, gating thresholds, or denominators. When monitoring change, use the same laboratory whenever possible and compare the complete report rather than only one number.
Preparation, Sample Handling, and Timing
Most patients do not need to fast. Continue medicines unless the ordering clinician gives different instructions, because stopping corticosteroids, immune suppressants, antivirals, or other treatment without guidance can be unsafe. Tell the clinician and laboratory about recent vaccines, infections, transfusions, immune therapies, and medication changes.
The sample is usually collected in a tube containing an anticoagulant such as EDTA or heparin. Flow-cytometry tests depend on living, intact cells, so transport and processing time matter more than they do for many routine chemistry tests. The ordering center may require collection on specific weekdays or before a daily courier cutoff. Samples sent over long distances may need special packaging and temperature control.
Before collection, useful questions include:
- Does the sample need to arrive within a specified number of hours?
- Is the test available every day or only on scheduled runs?
- Will the laboratory report CD4 and CD8 subsets separately?
- Is an absolute activated-cell count included?
- What method-specific reference interval will appear on the report?
- Should a lymphocyte subset panel or complete blood count be drawn at the same time?
Timing should match the clinical question. During acute illness, a sample may document the current activation state. During follow-up, clinicians may repeat it after treatment or at a comparable point in a therapy cycle. A single isolated value is less informative than a trend when the condition changes over time.
Turnaround varies. Some hospital laboratories can report routine flow cytometry within one or two days, while specialized panels sent to reference laboratories may take several days. Urgent treatment decisions in suspected HLH, sepsis, or severe infection should not be delayed solely while waiting for this result.
Follow-Up and When Care Is Urgent
Follow-up depends on why the test was ordered. A specialist may compare the activated T-cell result with a complete blood count, liver tests, ferritin, triglycerides, fibrinogen, CRP, soluble IL-2 receptor, CXCL9, viral studies, cultures, imaging, or genetic testing. The combination should answer a clinical question: Is immune activation present, is it improving, and what is driving it?
A reasonable discussion with the ordering clinician includes:
- Which T-cell subset was abnormal?
- Was the result mildly or markedly outside the laboratory’s interval?
- Could a recent infection, vaccination, or medicine explain it?
- Does the pattern fit the symptoms and other test results?
- Is repeat testing useful, and should it use the same laboratory?
- Which diagnosis is being considered, and what evidence is still missing?
An abnormal activated T-cell marker result alone is not an emergency. Symptoms and organ function determine urgency. Seek prompt medical assessment for persistent high fever, shortness of breath, confusion, fainting, severe weakness, unusual bleeding, rapidly spreading rash, jaundice, severe abdominal pain, or a sudden decline during an infection or immune therapy. These features can signal serious infection, hyperinflammation, treatment toxicity, or organ involvement and require evaluation beyond a flow-cytometry report.
For stable patients, the most useful next step is usually not repeated broad immune testing without a plan. It is targeted evaluation based on history, examination, exposure risks, medication timing, and the rest of the laboratory pattern. HLA-DR and CD38 results add evidence of T-cell activation; they do not replace the clinical work needed to find its cause.
References
- Frequency of HLA-DR+CD38hi T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders 2024 (Clinical Study)
- T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis 2021 (Clinical Study)
- Persistent High Percentage of HLA-DR+CD38high CD8+ T Cells Associated With Immune Disorder and Disease Severity of COVID-19 2021 (Clinical Study)
- Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment 2022 (Clinical Study)
- HIV DNA positively correlates with HLA-DR+CD8+ T lymphocytes over 8-year suppressive antiretroviral therapy 2023 (Clinical Study)
- Flow Cytometry Blood Cell Identification 2024 (Review)
Disclaimer
This article provides general information about activated T-cell marker testing and does not diagnose or treat any condition. HLA-DR and CD38 results are method-dependent and must be interpreted by a qualified clinician with symptoms, medications, other laboratory findings, and the reason for testing. Seek urgent medical care for severe or rapidly worsening symptoms regardless of the test result.
